Cargando…
Cancer vaccines: Are we there yet?
For nearly two decades there has been an abundance of research and clinical development programs underway to develop active specific immunotherapies, to educate the patient’s immune response, specifically the T-cell immunity and memory, to recognize and destroy tumor cells by cell-mediated cellular...
Autor principal: | Hanna, Jr., Michael G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551894/ https://www.ncbi.nlm.nih.gov/pubmed/22854657 http://dx.doi.org/10.4161/hv.21660 |
Ejemplares similares
-
50 States or 50 Countries: What Did We Miss and What Do We Do Now?
por: Burkle, Frederick M., et al.
Publicado: (2020) -
Can the exome and the immunome converge on the design of efficient cancer vaccines?
por: Kroemer, Guido, et al.
Publicado: (2012) -
Fifth Vaccine Renaissance introduction
por: De Groot, Annie S.
Publicado: (2012) -
Human Vaccines & Immunotherapeutics: News
por: Riedmann, Eva M.
Publicado: (2013) -
Reflection on modern methods: risk ratio regression—simple concept yet complex computation
por: Mittinty, Murthy N, et al.
Publicado: (2022)